RCKT Rocket Pharmaceuticals Inc
Company Analysis
Latest News
🟢 Rocket Pharmaceuticals is trading 10.13% up today after positive Phase 2 Danon disease safety update
Rocket Pharmaceuticals is trading 10.13% up today at $3.42 following a positive Phase 2 safety update for its Danon disease treatment candidate, RP-A501. •...
🟢 Rocket Pharmaceuticals is trading 5.5% up today on positive Phase 2 Danon disease safety update
Rocket Pharmaceuticals is trading 5.5% up at $3.28 after the company provided a positive clinical safety update for RP-A501 in its pivotal Phase 2 Danon...
Rocket Pharma Reports Positive Safety Data for RP-A501 in Phase 2 Danon Disease Trial
Rocket Pharmaceuticals announced a positive clinical safety update for its pivotal Phase 2 trial of RP-A501, an investigational gene therapy for Danon disease....
🟢 Rocket Pharmaceuticals is trading 6.8% up today with no clear catalyst yet
Rocket Pharmaceuticals is trading 6.8% up at $3.32 in pre-market action, following last Friday’s close at $3.11. • There are currently no fresh...
🟢 Rocket Pharmaceuticals is trading 8.3% up today with no clear catalyst identified yet
Rocket Pharmaceuticals is trading 8.3% higher at $3.40 today, despite a lack of fresh company-specific news, earnings, or regulatory headlines to explain the...
🔴 Rocket Pharmaceuticals is trading 5.1% down today amid broader biotech and market weakness
Rocket Pharmaceuticals is trading 5.1% down at $3.46 as high-risk growth names face selling pressure amid broader market and biotech sector weakness. • No...
🔴 Rocket Pharmaceuticals is trading 5.1% down today as investors take profits after a recent biotech rally
Rocket Pharmaceuticals is trading 5.1% down at $3.71 as investors continue to take profits in the biotech sector following a strong recent rally. • The move...
🔴 Rocket Pharmaceuticals Inc is trading 6.92% down
RCKT is trading at $3.90, down 6.92%.
🟢 RCKT is trading 5% up today with no clear company-specific catalyst
RCKT is trading about 5% up now at $3.70, continuing a steady rebound from late June lows. Recent coverage focuses on its longer-term upside potential and...
Rocket Pharmaceuticals Appoints New Principal Accounting Officer
Rocket Pharmaceuticals announced the resignation of John Militello, its VP of Finance and Principal Accounting Officer, and the subsequent appointment of...
🟢 RCKT jumps 5.3% pre-market on continued momentum from recent FDA gene therapy approval
• RCKT is trading at $3.55 (up 5.3%) in pre-market, extending its rebound following the recent FDA accelerated approval of Kresladi, its first commercial gene...
🟢 RCKT is trading 8.3% up today as it rebounds from recent weakness
RCKT is trading at $3.52 (8.3% up) in pre-market, rebounding from recent weakness following FDA-related volatility and a wider Q1 loss reported earlier this...
🔴 RCKT is trading 6.9% down today, extending a pullback amid broader market weakness
RCKT is trading at $3.03 (6.9% down), extending a pullback from gains seen earlier in June. • The move appears to be driven by continued volatility following...
🔴 RCKT is trading 5.3% down today after being dropped from the S&P Biotechnology Select Industry Index
RCKT is trading at $3.29 (-5.33%) today following the announcement that S&P Dow Jones Indices will remove Rocket Pharmaceuticals from the S&P Biotechnology...
Rocket Pharmaceuticals Dropped From S&P Biotech Index, Triggering Passive Fund Sales
S&P Dow Jones Indices removed Rocket Pharmaceuticals, Inc. from the S&P Biotechnology Select Industry Index late on June 21, 2026. This change becomes...
🟢 Rocket Pharmaceuticals Inc makes sharp 10.4% jump
RCKT is trading at $3.09, up 10.4% versus the comparison close of $2.80 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 Rocket Pharmaceuticals Inc is trading 5.4% up today with no clear company-specific catalyst found
Rocket Pharmaceuticals Inc is trading at $2.95 (+5.36%) following a rise from its $2.80 close on June 16, 2026, despite a lack of fresh company-specific news...
🟢 Rocket Pharmaceuticals Inc is trading 5.3% up today after closing the $180 million sale of its Priority Review Voucher
Rocket Pharmaceuticals Inc is trading 5.3% up at $2.80 following the announcement that it has closed the sale of its Rare Pediatric Disease Priority Review...